Answers are grounded in this paper and cite their sources.
Type 1 diabetes (T1D) is an organ-specific autoimmune disease caused by T cell-mediated pancreatic β-cell destruction. To evaluate the effects of 2-Deoxy-D-Glucose (2DG), a glycolytic inhibitor, on immune cells in autoimmune diabetes, 2DG was orally administered to two T1D mouse models. In a cyclophosphamide-induced T1D model in male non-obese diabetic (NOD) mice, oral 2DG treatment significantly suppressed autoimmune insulitis and diabetes. 2DG treatment showed a significant decrease in the frequencies of CD44 hi CD4 + T cells and CD11b + macrophages, and PD-1 expression level on B cells. Conversely, 2DG-treated mice showed a significant increase in the frequencies of Foxp3 + CD4 + regulatory T cells (Tregs) and PD-L1 + CD11b + macrophages. In addition, Integrin β7 expression level on CD8 + T cells was significantly reduced in 2DG-treated mice. Next, in female NOD mice, a spontaneous T1D model, oral 2DG treatment significantly suppressed autoimmune diabetes progression with a reduction of insulitis. The frequencies of CD11b + macrophages and CD11c + dendritic cells were significantly reduced in 2DG-treated mice. Notably, 2DG treatment significantly increased the frequency of Foxp3 + CD4 + Tregs in both splenocytes and PLN cells. These results suggest that 2DG may suppress autoimmunity and have therapeutic potential in T1D progression by affecting immune cells. In addition, reduced glucose uptake was demonstrated only in B cells, suggesting that metabolic regulation in B cells may contribute to the protective effects of 2DG.
No takes yet. Share an insight, caveat, or question.
Maruyama et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: